What caused the CTX.TO stock jump today?

The spike followed Crescita’s announcement of a definitive all-cash arrangement with ClinActiv targeting **C$0.80** per share, triggering heavy volume and a **56.99%** pre-market gain on TSX.

Is the CTX.TO stock takeover certain?

No. The Arrangement requires shareholder and court approvals and other closing conditions. The Board recommends the deal but completion is subject to customary regulatory and transactional conditions.

How does Meyka AI view CTX.TO stock?

Meyka AI rates CTX.TO **69.80/100 (Grade B, HOLD)**. The model balances deal-based upside against fundamentals and projects a 12‑month price near **C$0.42**. Forecasts are projections, not guarantees.

What is the near-term price target from the deal for CTX.TO stock?

The Arrangement sets a headline target of **C$0.80** per share with a minimum purchase price of **C$0.75**, which sets the practical near-term valuation band until closing or competing bids emerge.

CA Stocks

CTX.TO stock jumps 56.99% pre-market on $0.80 offer: 9.6% upside 17 Mar 2026

ByHuzaifa Zahoor March 17, 2026March 17, 2026

The CTX.TO stock surge led pre-market top-gainer lists on 17 Mar 2026 after Crescita Therapeutics (TSX: CTX) disclosed an all-cash arrangement with ClinActiv that targets C$0.80 per share. The market reacted with a 56.99% jump to C$0.73 on volume of 853,301 shares versus a 50-day average of 24,864, suggesting takeover speculation and liquidity drove the move. We unpack the deal, valuation, financials and what the move means for investors in Canada’s TSX healthcare cohort.